Eli Lilly to build $5 billion Virginia manufacturing facility
Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli…
Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy…
CPI report health care inflation rises
Jose Luis Pelaez Inc | Digitalvision | Getty Images Health-care inflation is fueling higher coverage costs, setting the…
What’s likely to move the market in the next trading session
Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and…
Wegovy-maker Novo Nordisk to cut around 9,000 jobs
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg |…
Novo Nordisk’s Martin Holst Lange previews obesity pill
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…
Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart…
Eli Lilly’s Daniel Skovronsky talks obesity pill data
The Eli Lilly headquarters in Indianapolis, Indiana, on Aug. 15, 2024. AJ Mast | Bloomberg | Getty Images…
Eli Lilly’s obesity pill will rival Novo Nordisk’s oral Wegovy drug
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March…
Meta shares fall on AI restructuring report, while Lilly shrugs off Novo’s Ozempic price move
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Eli Lilly obesity pill orforglipron led to 12% weight loss
Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12%…
Eli Lilly earnings are coming Thursday. What top analysts expect
Many on Wall Street expect that Novo Nordisk ‘s loss has been Eli Lilly ‘s gain, and this…